Every 8-K that Advanced Biomed Inc. (ADVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADVB filings page.
Advanced Biomed Inc. reports that it is terminating a previously established equity purchase arrangement with Helena Global Investment Opportunities I Ltd. The Purchase Agreement, signed on June 6, 2025, had allowed the company, at its discretion, to issue and sell up to $25,000,000 of common stock with a par value of $0.001 per share.
On July 14, 2026, the company delivered a Termination Notice under a contractual provision permitting termination with five trading days’ prior written notice, provided there were no outstanding Advance Notices and all amounts, including all Commitment Fee Shares, had been paid. These conditions were satisfied, and the company states it has not issued or sold any shares to the investor pursuant to any Advance under the agreement other than the Commitment Fee Shares. The termination becomes effective on July 21, 2026.
Advanced Biomed Inc. reported the results of its annual stockholder meeting held on June 30, 2026, where all five proposals passed. Stockholders elected five directors, approved executive compensation on a non-binding basis, and chose annual advisory votes on pay.
Holders of 1,422,573.80 common shares were represented, about 86.105% of the 1,652,133 shares outstanding and entitled to vote as of May 29, 2026, establishing a quorum. Stockholders also ratified WWC, P.C. as auditor for the fiscal year ending June 30, 2026, and approved a potential adjournment of the meeting if needed.
Advanced Biomed Inc. has entered into a material definitive agreement to sell 100% of the issued and outstanding shares of its wholly owned Taiwan subsidiary, Advanced Biomed Inc. (Taiwan), for an aggregate purchase price of US$490,000. This entity conducts the company’s biomedical research and development operations, including the A+PerfusC integrated perfusion 3D cell culture platform.
The buyer is described as an unrelated third party, and the transaction is expected to close within three months from June 30, 2026, subject to conditions in the share purchase agreement. After this disposition, Advanced Biomed plans to continue operating its remaining businesses, including AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.
Advanced Biomed Inc. completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited by issuing 270,000 shares of its common stock at $4.00 per share, for an estimated consideration of $1,080,000. The shares were issued under Section 4(a)(2) of the Securities Act.
The company is undertaking a strategic pivot from life sciences to artificial intelligence development. In connection with this change, former CEO and chairman Yi Lu entered into a mutual separation, receiving 39,999 shares of common stock as severance, and Xiaomin Chen was appointed as the new Chief Executive Officer, director and Chairman of the Board with compensation of $12,000 per month.
Advanced Biomed Inc. entered into an unsecured Loan Agreement with Jie Wang under which the lender provided a US$600,000 short-term loan. The loan carries a 10% annual interest rate, runs for six months from the disbursement date, and may be extended once for an additional six months by mutual written agreement.
The company must repay the full US$600,000 principal plus accrued interest on or before the maturity date but can prepay at any time without penalty, with partial prepayments applied first to interest and then principal. Advanced Biomed plans to use the loan proceeds for operations, and the agreement is governed by New York law.
Advanced Biomed Inc. entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, which provides AI-powered financial verification and audit solutions. The seller will receive 270,000 shares of Advanced Biomed common stock, valued at $4.00 per share, for an estimated total of $1,080,000.
The acquisition is conditioned on completing financial and legal due diligence of Acellent and obtaining all required regulatory approvals, so the transaction has not yet closed.
Advanced Biomed Inc. reported leadership changes effective March 25, 2026. Steven I-Fang Cheng resigned as both a member of the Board of Directors and as Chief Technology Officer. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the Board, following a recommendation from the Nominating Committee, appointed Chief Financial Officer Mingze Yin as a director. The company disclosed that Mr. Yin has no family relationships with other leaders, no special arrangements leading to his appointment, and no related-party transactions requiring disclosure.
Advanced Biomed Inc. reported that Nasdaq has determined the company regained compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company implemented a reverse stock split completed on February 20, 2026, after shareholders approved the action on January 12, 2026.
Following the reverse split, the company’s common stock maintained a closing bid of at least $1.00 per share, satisfying Nasdaq’s rule. As a result, Advanced Biomed’s stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor under Listing Rule 5815(d)(4)(A).
Advanced Biomed Inc. implemented a 1-for-20 reverse stock split of its common stock, effective at the open of trading on February 20, 2026, to consolidate every 20 issued and outstanding shares into 1 share with the same par value.
The capital structure change does not alter the number of authorized shares and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement. After the reverse split, total issued and outstanding common shares change from 27,290,710 to approximately 1,364,536, while the stock continues trading on the Nasdaq Capital Market under the symbol ADVB.
Advanced Biomed Inc. filed an amended current report describing share issuance tied to a previously disclosed equity line of credit. The company has an agreement with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. for an equity line of up to $25,000,000 in common stock.
On January 30, 2026, Advanced Biomed issued 1,650,710 shares of common stock to the investor as a commitment fee under the agreement, with an aggregate value of $500,000 at the time of issuance. These shares were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act of 1933.
Advanced Biomed Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors on January 28, 2026, to issue and sell 4,000,000 shares of common stock at $0.062 per share, for total proceeds of $248,000.
The transaction closed and the shares were issued on January 29, 2026. The shares were sold in a private placement relying on exemptions from U.S. registration under Section 4(a)(2) of the Securities Act and Regulation S.
Advanced Biomed Inc. entered into a Supplemental Agreement related to its previously announced spin-off of Advanced Biomed (HK) Limited. The Hong Kong subsidiary acknowledged that it owes the company an aggregate $6,925,549, reflecting its accounts receivable as of the original spin-off date and the new agreement date.
Under this Supplemental Agreement, Advanced Biomed (HK) Limited irrevocably agrees to repay the entire debt on or before the first anniversary of January 26, 2026. This supplements the prior deal in which Advanced Biomed agreed to sell 100% of the Hong Kong subsidiary’s shares for an aggregate purchase price of US$23,000. The board of directors unanimously approved the Supplemental Agreement.
Advanced Biomed Inc. reported that it has failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share by the January 14, 2026 compliance deadline. Nasdaq staff has notified the company that its common stock is scheduled for delisting and trading suspension on January 27, 2026 unless the decision is reversed.
The company appealed the delisting notice on January 21, 2026, which temporarily stayed any suspension and the filing of a Form 25-NSE while a Nasdaq Hearings Panel reviews the case. Advanced Biomed plans to present a remediation plan, including a reverse stock split that stockholders approved on January 12, 2026 and that is expected to become effective on or after February 13, 2026. The company cautions that there is no assurance the Panel will allow continued listing or that it will regain compliance within any time period that may be granted.
Advanced Biomed Inc. filed a current report describing that it issued a press release announcing the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform for precision medicine and drug discovery. The filing mainly serves to furnish this press release as an exhibit for investors and other stakeholders.